Eterna Therapeutics (ERNA) Competitors

Eterna Therapeutics (NASDAQ:ERNA) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk.

Does the media refer more to ERNA or VNRX?

In the previous week, Eterna Therapeutics and Eterna Therapeutics both had 5 articles in the media. VolitionRx's average media sentiment score of 0.75 beat Eterna Therapeutics' score of -0.02 indicating that VolitionRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eterna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VolitionRx	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, ERNA or VNRX?

Eterna Therapeutics has higher earnings, but lower revenue than VolitionRx. VolitionRx is trading at a lower price-to-earnings ratio than Eterna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eterna Therapeutics	$535K	276.27	-$21.67M	-$8.31	-0.29
VolitionRx	$1.31M	46.93	-$35.32M	-$0.27	-2.21

Which has more risk and volatility, ERNA or VNRX?

Eterna Therapeutics has a beta of 5.56, suggesting that its share price is 456% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Do insiders and institutionals believe in ERNA or VNRX?

70.6% of Eterna Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of VolitionRx shares are owned by institutional investors. 1.5% of Eterna Therapeutics shares are owned by company insiders. Comparatively, 10.4% of VolitionRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer ERNA or VNRX?

VolitionRx received 15 more outperform votes than Eterna Therapeutics when rated by MarketBeat users.

Company	Underperform	Outperform
Eterna Therapeutics	N/A	N/A
VolitionRx	Outperform Votes 15 20.83%	Underperform Votes 57 79.17%

Is ERNA or VNRX more profitable?

VolitionRx has a net margin of -2,321.14% compared to Eterna Therapeutics' net margin of -7,513.88%.

Company	Net Margins	Return on Equity	Return on Assets
Eterna Therapeutics	-7,513.88%	N/A	-117.48%
VolitionRx	-2,321.14%	N/A	-163.39%

Do analysts rate ERNA or VNRX?

VolitionRx has a consensus target price of $3.50, indicating a potential upside of 487.25%. Given VolitionRx's stronger consensus rating and higher probable upside, analysts plainly believe VolitionRx is more favorable than Eterna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eterna Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
VolitionRx	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

VolitionRx beats Eterna Therapeutics on 10 of the 16 factors compared between the two stocks.